BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.

ABSTRACT:

Background

Mutations in BRCA1 and BRCA2 are associated with better survival in ovarian cancer (OC) patients due to a better response to platinum-based chemotherapy. However, the impact of the BRCA1/2 mRNA-expression is not well characterized in OC.

Patients and methods

We investigated BRCA1/2 mRNA-expression in 12 non-neoplastic fallopian tubes and 201 epithelial OCs in relation to their clinical characteristics.

Results

We found higher BRCA1/2 mRNA-expression in OCs compared to controls (P = 0.011, P < 0.001, respectively). BRCA1 mutated OCs exhibited lower BRCA1 (P = 0.014) but higher BRCA2 mRNA-expression (P = 0.001). Low BRCA1-expression was associated with favorable overall survival (OS) (P = 0.012) and low BRCA2-expression with better progression-free survival (

SUBMITTER: Tsibulak I 

PROVIDER: S-EPMC6173779 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature